Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Not Yet Opened 08-07 16:00:00 EDT

81.29

+1.63

+2.05%

High81.35	Low79.65	Vol762.75M
Open79.65	D1 Closing79.65	Amplitude2.13%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O17.49B	T/O Rate--	Tradable Shares0.00
P/B7.759012	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":81.28564,"timestamp":1786132799999,"preClose":79.654175,"halted":0,"volume":762748377,"delay":0,"changeRate":0.020482,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":1.631462,"latestTime":"08-07 16:00:00 EDT","open":79.65422,"high":81.35329,"low":79.65422,"amount":17485960997.676838,"amplitude":0.021331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.759012,"peRate":-93.260942,"turnoverRate":0.021759,"increases":330,"decrements":166,"flats":17,"marketCap":2073110740640.625,"floatMarketCap":1892936717327.3125},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"1175410099","title":"BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1175410099","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175410099?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:08","pubTimestamp":1786331293,"startTime":"0","endTime":"0","summary":"BOCOM International has released a research report raising its price target for BEONE MEDICINES (06160) from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.In the second quarter, Zanubutinib...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK0239","688235","LU0307460666.USD","BK1161","LU1251922891.USD","BK1588","LU0228659784.USD","LU1303224171.USD","ONC","BK4588","BK4585","LU1770034418.SGD","BK1500","LU1719994722.HKD","KURE","LU2328871848.SGD","BK4139","LU0588546209.SGD","BK4526","BK1583","LU0828237510.HKD","06160","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658606890","title":"Daiichi Sankyo, Innovent enter exclusive agreement for Vanflyta in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658606890","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658606890?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:35","pubTimestamp":1786322111,"startTime":"0","endTime":"0","summary":"Innovent Biologics (IVBXF) and Daiichi Sankyo (DSNKY) have entered into an exclusive agreement for the commercialization of Vanflyta in China. Unde...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/daiichi-sankyo-innovent-enter-exclusive-agreement-for-vanflyta-in-china-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/daiichi-sankyo-innovent-enter-exclusive-agreement-for-vanflyta-in-china-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IVBXF","BK4007","DSNKY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658811606","title":"Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658811606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658811606?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:30","pubTimestamp":1786321807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM) and Encompass Health (E...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mirum-pharmaceuticals-mirm-and-encompass-health-ehc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mirum-pharmaceuticals-mirm-and-encompass-health-ehc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1983260115.SGD","MIRM","BK4581","HCSG","LU0128526141.USD","LU2237957811.SGD","BK4137","EHC","LU0054578231.USD","LU2237957902.USD","BK4139","BK4585","XBI","BK4185","SGXZ23171101.USD","XLV","LU0029874061.USD","SG9999004303.SGD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658034756","title":"Percheron Therapeutics names Michael Baker CEO as James Garner moves to non-executive role","url":"https://stock-news.laohu8.com/highlight/detail?id=2658034756","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658034756?lang=en_us&edition=fundamental","pubTime":"2026-08-10 06:43","pubTimestamp":1786315381,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics ( ($AU:PER) ) just unveiled an announcement. Percheron Therapeutics has announced a leadership transition, with current Chie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-names-michael-baker-ceo-as-james-garner-moves-to-non-executive-role?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-names-michael-baker-ceo-as-james-garner-moves-to-non-executive-role?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658603127","title":"AVITA Medical to Host Investor Webinar Briefing-Rcel.o","url":"https://stock-news.laohu8.com/highlight/detail?id=2658603127","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658603127?lang=en_us&edition=fundamental","pubTime":"2026-08-10 06:33","pubTimestamp":1786314780,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260809:nASX86DCMG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nASXbBPvYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658603130","title":"AVITA to Participate at Canaccord Genuity Growth Conference-Rcel.o","url":"https://stock-news.laohu8.com/highlight/detail?id=2658603130","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658603130?lang=en_us&edition=fundamental","pubTime":"2026-08-10 06:24","pubTimestamp":1786314288,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260809:nASXwT9sz","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nASX9H1Y4l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658603584","title":"Avita Medical Hosts Investor Webinar Briefing Led by CEO Cary Vance, CFO David O’Toole","url":"https://stock-news.laohu8.com/highlight/detail?id=2658603584","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658603584?lang=en_us&edition=fundamental","pubTime":"2026-08-10 06:00","pubTimestamp":1786312814,"startTime":"0","endTime":"0","summary":"Avita Medical hosts investor webinar briefing led by CEO Cary Vance, CFO David O’TooleAvita Medical will host an investor webinar briefing on Aug. 12, 2026 at 4:00 p.m. Pacific Time.The session will r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nNDL79H6tP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","LU0314104364.USD","BCDF","IE00B3QW5Z07.USD","BK4112","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4585","NDAQ","BK4139","RCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658603881","title":"Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 Sanreco Trial of Divesiran in Polycythemia Vera","url":"https://stock-news.laohu8.com/highlight/detail?id=2658603881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658603881?lang=en_us&edition=fundamental","pubTime":"2026-08-10 05:00","pubTimestamp":1786309202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nTUA3KRNXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNCF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658160358","title":"Novavax (NVDA) Could Be 42% Undervalued Following Losses And Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2658160358","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658160358?lang=en_us&edition=fundamental","pubTime":"2026-08-10 04:25","pubTimestamp":1786307137,"startTime":"0","endTime":"0","summary":"What the latest Novavax earnings mean for shareholders\nNovavax (NVAX) just delivered a sharp turn in its financial story. Second quarter 2026 results showed revenue of US$56.7 million and a shift from net income to a net loss, alongside a fresh shelf registration filing.\nSee our latest analysis for Novavax.\nThe latest earnings release and shelf registration have come alongside mixed recent trading for Novavax. The share price has risen 2.71% over the last day and 8.61% over the past week,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavax-nvda-could-be-42-undervalued-following-losses-and-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/novavax-nvda-could-be-42-undervalued-following-losses-and-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVAX","BK4139","BK4585","BK4547","BK4568","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670494","title":"Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670494","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670494?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:26","pubTimestamp":1786292804,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance.\nSee our latest analysis for Arcutis Biotherapeutics.\nThe latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-could-be-31-undervalued-followi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-could-be-31-undervalued-followi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TACU","ARQT","CDIG","TSPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658562677","title":"Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Achieve Life Sciences (ACHV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658562677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658562677?lang=en_us&edition=fundamental","pubTime":"2026-08-09 21:20","pubTimestamp":1786281629,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PROCEPT BioRobotics (PRCT) and Achieve Life Scienc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-procept-biorobotics-prct-and-achieve-life-sciences-achv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-procept-biorobotics-prct-and-achieve-life-sciences-achv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","PRCT","ACHV","LU0029874061.USD","LU0128526141.USD","LU2324357040.USD","XLV","BK4082","HCSG","BK4588","XBI","BK4585","BK4581","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672068","title":"Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672068?lang=en_us&edition=fundamental","pubTime":"2026-08-09 20:41","pubTimestamp":1786279307,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancersSilexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nNDL4dLvQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658147672","title":"Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658147672","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658147672?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:36","pubTimestamp":1786264567,"startTime":"0","endTime":"0","summary":"Kodiak Sciences has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation, advancing a bispecific IL-6/VEGF therapy through a pivotal analysis that will inform regulatory paths.\nAn interesting aspect of this update is how PEAK and the complementary PINNACLE study are structured to span a broad spectrum of MESI severity, from mild to more advanced disease, potentially broadening the therapy’s clinical relevance if...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/kodiak-sciences-kod-is-up-91-after-advancing-ksi-101-phase-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/kodiak-sciences-kod-is-up-91-after-advancing-ksi-101-phase-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KSI","BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672196","title":"Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672196","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672196?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:33","pubTimestamp":1786264417,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) has drawn fresh investor attention after receiving U.S. Food and Drug Administration clearance to begin a Phase 1 trial of DYNE-302 for facioscapulohumeral muscular dystrophy, a rare muscle disease without approved treatments.\nSee our latest analysis for Dyne Therapeutics.\nAt a share price of $26.25, Dyne Therapeutics has seen strong recent momentum, with a 30 day share price return of 12.08% and a 1 year total shareholder return of 135.22%, which suggests investor...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/dyne-therapeutics-dyn-gets-fda-clearance-with-valuation-ques","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/dyne-therapeutics-dyn-gets-fda-clearance-with-valuation-ques","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4505","BK4588","DCF","SPHQ","LABU","DYN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658567178","title":"Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2658567178","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658567178?lang=en_us&edition=fundamental","pubTime":"2026-08-09 14:40","pubTimestamp":1786257653,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals has delivered a 63.5% gain over the past year, yet the broader valuation checks and current market multiples suggest the stock is not an obvious bargain at today’s price of US$20.40.\n\nThe 63.5% one year return points to strong recent optimism already reflected in Syndax Pharmaceuticals' share price.\nProgress on its oncology pipeline and upcoming clinical data can support expectations for future revenue, while the execution and clinical risks around those same programs...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-looks-stretched-as-its-63","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-stock-looks-stretched-as-its-63","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658679762","title":"GRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2658679762","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658679762?lang=en_us&edition=fundamental","pubTime":"2026-08-09 12:34","pubTimestamp":1786250074,"startTime":"0","endTime":"0","summary":"Regulatory milestone puts focus on GRAIL stock\nGRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test.\nSee our latest analysis for GRAIL.\nThe FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GRAL","BK4139","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101035030","title":"Goldman Sachs Competitor Adjusts BeOne Medicines Target Upward, Bullish Ratings Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1101035030","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101035030?lang=en_us&edition=fundamental","pubTime":"2026-08-09 09:50","pubTimestamp":1786240220,"startTime":"0","endTime":"0","summary":"A financial research report from a major investment bank indicates that, considering the strong growth of BeOne Medicines (stock code: 06160) drug sales and improved cost control, its net profit...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU1719994722.HKD","BK4588","06160","ONC","BK1588","LU1251922891.USD","EWH","BK4585","LU1969619763.USD","LU1770034418.SGD","LU0588546209.SGD","LU0307460666.USD","BK4139","BK0239","LU1303224171.USD","LU0828237510.HKD","688235","LU0228659784.USD","BK4526","KURE","BK1161","BK1500","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658676710","title":"Ardelyx Stock Leads These Financially Fit Penny Stocks Worth A Closer Look","url":"https://stock-news.laohu8.com/highlight/detail?id=2658676710","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658676710?lang=en_us&edition=fundamental","pubTime":"2026-08-09 07:24","pubTimestamp":1786231476,"startTime":"0","endTime":"0","summary":"With inflation expectations in the US edging down and wage growth coming in softer than many anticipated, interest rate expectations are shifting again. That puts smaller, financially healthier penny stocks in an interesting spot as investors reassess where to find potential growth and resilience. This article looks at three stocks from the Financially Fit Penny Stocks screener that combine low share prices with balance sheet strength.\nThe three stocks covered below are just a starting...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-stock-leads-these-financially-fit-penny-stocks-worth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-stock-leads-these-financially-fit-penny-stocks-worth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4149","TBLA","BK4077","HYLN","ARDX","BK4096","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658203676","title":"3 Australian Growth Stocks With High Insider Ownership Investors May Want To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2658203676","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658203676?lang=en_us&edition=fundamental","pubTime":"2026-08-09 05:29","pubTimestamp":1786224541,"startTime":"0","endTime":"0","summary":"Global manufacturing and commodity demand has shifted again, with Taiwan and China still exporting strongly in AI, semiconductors and broader technology. That keeps growth stories very much alive. Investors who like fast growing stocks with high insider ownership may see this as a chance to focus on companies where both analysts and management currently hold optimistic views. This article highlights three such stocks from the screener.\nThe stocks covered below are just a starting sample, and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/3-australian-growth-stocks-with-high-insider-ownership-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","VAP.AU","BK4211","DACE.AU","TLX","IMLC.AU","PDI.AU","QRE.AU","OZF.AU","XJO.AU","IISV.AU","STW.AU","QFN.AU","BK7145","BBOZ.AU","E200.AU","ZYAU.AU","BK4139","GLF.AU","ISBC","XAO.AU","IOZ.AU","SLF.AU","GEAR.AU","OZR.AU","XKO.AU","EIGA.AU","TLX.AU","VAS.AU","BEAR.AU","IIGF.AU","BK7104","GIVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567890","title":"Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567890?lang=en_us&edition=fundamental","pubTime":"2026-08-08 22:40","pubTimestamp":1786200025,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","BK4139","IE00BJJMRZ35.SGD","BBH","IE00BFTCPJ56.SGD","RVMD","IE0009354923.USD","IE00B2B36J28.USD","LU0109394709.USD","IE0002141913.USD","PTH","IE00B4R5TH58.HKD","LFSC","LU0320765992.SGD","IDNA","LU0889565916.HKD","IE00BJT1NW94.SGD","SYRE","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction